Recurrent pericarditis

Article written and reviewed by Dr Luca Moretti

The recurrent pericarditis is the reappearance of pericarditis after a documented episode and an interval of remission. The classic definition requires a symptom-free period of at least four to six weeks, followed by a new manifestation supported by objective evidence of activity. The requirement for remission separates recurrence from incessant pericarditis, in which inflammation never truly resolves. Returning pain alone is not sufficient to demonstrate a relapse: its clinical significance depends on concordance with examination, biomarkers, and imaging.

It is one of the most relevant outcomes of acute pericarditis. After a first idiopathic episode, traditional series describe recurrence in approximately 15-30% of patients, with important variation related to selection, treatment, and outcome definition. Risk may increase after a first recurrence, but these percentages are not an individual prediction and should not be applied indiscriminately to patients treated with modern strategies. Some people experience only one new episode; others go through years of flares, treatment dependence, and activity limitation.

Its prognostic meaning is twofold. In idiopathic forms, survival and risk of constriction are generally favorable, whereas the burden of pain, healthcare visits, drug exposure, and loss of quality of life may be high. Understanding of immune mechanisms and studies of colchicine and interleukin-1 blockade have changed treatment. The goal is not only to stop an attack, but to achieve durable remission with the lowest possible medication burden, without automatically attributing every subsequent pain episode to the same disease.

Etiology, predisposition, and immunopathogenetic basis

Recurrence describes the behavior over time of an inflammatory process and does not by itself identify its cause. Many forms are defined as idiopathic because no agent or systemic disease emerges after appropriate evaluation. A first episode preceded by a viral illness may have an infectious trigger and subsequent predominantly immune-mediated reactivations; this does not prove repeated reinfection of the pericardium. The hypothesis of viral persistence, when considered, should not be turned into a general indication for serial serology or empirical antiviral treatment. Demonstrating an agent and establishing clinical plausibility remain separate questions.

Among secondary causes are connective tissue diseases, autoinflammatory diseases, post-cardiac injury syndromes, specific infections, and neoplastic or iatrogenic conditions. Lupus serositis may recur together with systemic activity; a postpericardiotomy syndrome may have immune-mediated flares after the initial injury. Tuberculosis and bacterial infections require particular attention when fever, large collections, or epidemiologic clues persist. In a patient with cancer, reappearance of fluid does not necessarily demonstrate an inflammatory recurrence: lymphatic obstruction, infiltration, and oncologic treatment can produce different clinical pictures.

The factors associated with recurrence include incomplete control of the previous episode, failure to use colchicine when appropriate, premature discontinuation, and particular patterns of corticosteroid exposure. These associations do not mean that the patient is responsible or that every recurrence was preventable. Intolerance, comorbidities, mandatory indications, and biological aggressiveness may condition treatment. Corticosteroids are often prescribed to more complex cases, making it difficult to completely separate drug effect from baseline severity. Prevention therefore requires cautious causal interpretation, not retrospective assignment of blame to a single prescription.

An important pathogenetic model involves innate immunity. Pericardial injury makes endogenous signals available that are recognized by resident and recruited cells. Initial activation promotes expression of mediators and components of the inflammatory machinery; subsequent signals may promote assembly of the NLRP3 inflammasome and activation of caspase-1, with maturation of interleukin-1 beta. Interleukin-1 alpha, also linked to the response to tissue injury, contributes to amplification. Persistence of these circuits may maintain a predisposition to flares even after the original trigger has disappeared. Experimental observations support the model without demonstrating one universal mechanism.

The interleukin-1 acts on endothelial, stromal, and immune cells, promoting leukocyte recruitment and production of additional mediators. The systemic response, to which interleukin-6 contributes, may present with fever and elevated CRP. This pattern helps explain a phenotype characterized by painful attacks, marked inflammation, and sometimes polyserositis. The efficacy of anakinra and rilonacept in selected patients provides therapeutic confirmation of the relevance of this pathway, but does not justify diagnosing a genetic inflammasome defect in everyone who responds to treatment.

The autoimmunity instead involves an adaptive response directed against self-components, in the setting of systemic disease or loss of tolerance following injury. The distinction between autoimmune and autoinflammatory disease is useful but not absolute: innate cells, lymphocytes, and tissues interact and phenotypes may overlap. Isolated low-titer autoantibodies do not define autoimmune pericarditis. A clinical picture with arthritis, skin lesions, complement abnormalities, and organ damage carries different weight and may require treatment of the systemic disease rather than control of a single cytokine alone.

The genetic predisposition is considered especially when there is early onset, family history, periodic fevers, serositis at multiple sites, or characteristic manifestations. Familial Mediterranean fever and tumor necrosis factor receptor-associated periodic syndrome are examples of conditions in which pericardial involvement may be part of a broader disease. However, most recurrent forms cannot automatically be equated with a monogenic syndrome. The significance of a variant depends on classification, penetrance, familial segregation, and phenotypic concordance; a variant of uncertain significance is neither a diagnosis nor a sufficient reason to radically change therapy.

At the level of local pathophysiology, each flare may produce edema, exudation, irritation of the surfaces, and pain, with a highly variable amount of effusion. The amount of fluid is not proportional to the suffering reported. Changes in compliance may be transient and do not imply irreversible accumulation of scar with every episode. Repeated attacks therefore do not necessarily lead to constriction. The likelihood of fibrotic outcomes depends strongly on the cause and biology of the process, whereas concomitant myocardial involvement adds a different risk mechanism that should be assessed separately.

Clinical manifestations and patient assessment

The history must demonstrate the sequence episode-remission-recurrence. Findings from the first attack, recovery, any treatment still being taken during the interval, and onset of new symptoms are documented. The remission required to define recurrent pericarditis must be followed by completion and discontinuation of anti-inflammatory therapy; reactivation during tapering instead falls within an incessant course. Duration of the interval, corticosteroid dose, and timing of reductions help distinguish recurrence, incessant disease, and medication dependence. The number of emergency department visits does not automatically equal the number of demonstrated episodes.

The pain of recurrence may resemble the initial pain, with respiratory and positional components, but is sometimes less intense or less typical. Previous experience makes many patients able to recognize a change, without replacing clinical verification. Some report a prodrome of fatigue or malaise; others rapidly develop pain and fever. Duration, interference with sleep, and functional limitation are important information for assessing disease burden and response, beyond the simple presence or absence of a chest twinge.

A febrile flare with elevated CRP and pleural or pericardial effusion suggests systemic inflammatory expression. Other presentations have only mildly altered markers and require greater contribution from imaging and differential diagnosis. A normal CRP does not justify denying the pain, but neither does it demonstrate that a biologic is required. Relationships with intercurrent infections, vaccinations, procedures, or medication changes should be recorded without automatically assigning causality based on temporal proximity. In many episodes, no precise trigger can be identified.

The treatment history specifies drugs, doses, and duration of each course. It is useful to distinguish a recurrence during colchicine at a tolerated dose from an attack appearing months after withdrawal, and disease not controlled despite an adequate regimen from treatment stopped because of diarrhea or interactions. Self-adjustment of corticosteroids, intermittent NSAID use, and medications that alter colchicine exposure are also investigated. Assessment of refractoriness cannot disregard these details: the term should describe a real and documented failure, not merely the fact that a drug appeared on a previous prescription.

Physical examination includes hemodynamic stability, temperature, rhythm, respiratory status, and signs of congestion. A friction rub may recur but is often absent during a single visit. New jugular venous distension, hypotension, pulsus paradoxus, or worsening dyspnea requires timely investigation for an effusive complication. Edema and ascites also point toward altered filling, whereas crackles and signs of low output may suggest myocardial involvement. A pre-existing diagnosis of recurrent pericarditis does not make triage of a new episode any less important.

The search for extracardiac signs is repeated over time because systemic disease may become evident years later. Joints, skin, mucosae, lymph nodes, abdomen, and clues of renal or vascular injury are assessed. Familial febrile attacks, recurrent abdominal pain, and other serositis may justify immunologic consultation. Gastrointestinal bleeding, muscle weakness, recurrent infections, and metabolic changes may instead indicate treatment toxicity. Pericardial disease and adverse effects may coexist, and distinguishing them is essential to prevent more intensive therapy from worsening overall function.

Assessment of quality of life includes absence from work, withdrawal from sport, sleep disturbance, concern about recurrence, and difficulty planning pregnancy or travel. Studies of patient-reported outcomes, including the dedicated RHAPSODY analysis, document that the burden is not limited to days with fever. A person may have normal cardiac function and a highly disabling disease. Quantifying these aspects helps select realistic therapeutic goals and assess benefits that a single CRP curve cannot represent.

Investigations and confirmation of recurrence

Confirmation begins with data contemporaneous with symptoms, preferably before a major change in treatment makes activity less recognizable, when the clinical situation permits. ECG, CRP, complete blood count, and echocardiographic assessment are the most common initial tools; troponin and further tests are selected according to presentation. Comparison with the remission state is essential. A minimal effusion unchanged for months does not have the same meaning as a new collection, and an already abnormal ECG cannot be counted again as evidence of every episode.

There is no single test for recurrence. The temporal component is added to the diagnosis of pericarditis according to a recognized framework. The 2025 ACC document considers a compatible presentation, typically pleuritic pain or a clinical equivalent, associated with at least one additional finding. The list summarizes these findings, whereas previously documented pericarditis and an intervening remission define the recurrent nature. It is not correct to use benefit from corticosteroids as an additional criterion because many inflammatory pains respond to these drugs.

Additional objective findings accompanying the clinical presentation in the 2025 ACC pathway for diagnosis of pericarditis.

• Pericardial friction rub.
• Typical electrocardiographic changes.
• Elevation of inflammatory markers.
• New or increasing pericardial effusion.
• Pericardial inflammation demonstrated by imaging.

The 2025 ESC guidelines instead distinguish definite clinical diagnosis, with a compatible presentation and more than one additional criterion, from possible diagnosis, with only one. They include friction rub, ECG changes, CRP elevation, new or worsening effusion, and pericardial findings on magnetic resonance imaging. Stating the framework avoids mixing different thresholds and clarifies why a presentation may require further investigation while remaining clinically suggestive. Recurrences sometimes have less evident signs than the first episode, especially during treatment; this increases the value of targeted testing without making confirmation unnecessary.

The CRP supports activity and may guide monitoring when it rises consistently with attacks. Very early sampling, local inflammation, or treatment already taken may limit sensitivity. When it has never been elevated, pursuing normalization provides no useful target and other evidence must be used. Conversely, an isolated increase must be contextualized: respiratory infections, systemic diseases, and other processes can cause it. Erythrocyte sedimentation rate changes more slowly and should not be used alone to decide every treatment reduction.

The troponin answers the question of myocardial injury, not isolated pericardial recurrence. If elevated, its trend, ventricular function, and possible ischemic or nonischemic causes are assessed. Palpitations, syncope, conduction abnormalities, or dysfunction require rhythm and myocardial evaluation proportional to risk. The label of recurrent pericarditis must not obscure associated myocarditis or a coronary syndrome. Even in a young patient with previous typical attacks, a substantial change in presentation may justify a different diagnostic pathway.

The echocardiogram documents collections, function, and hemodynamic consequences. Absence of fluid does not exclude inflammation; conventional ultrasound does not visualize all tissue abnormalities with the same sensitivity as magnetic resonance imaging. An enlarging effusion or compressive physiology changes management, whereas a minimal stable collection may have little relation to pain. If signs of constriction appear, respiratory Doppler assessment is integrated while accounting for loading and ventilation conditions. The goal is to understand the function of the pericardium-heart system, not merely to measure an anechoic space.

The magnetic resonance imaging is particularly useful in equivocal cases, in forms with normal markers, and before burdensome therapeutic decisions. Pericardial edema and LGE, interpreted by experienced operators, may support local inflammation not evident on basic testing. Persistence of LGE alone does not necessarily identify a clinical recurrence and does not automatically mandate an increase in medication; it may reflect residual abnormalities. Images must be correlated with symptoms, course, and therapy. Magnetic resonance imaging also contributes to the search for myocardial injury, whereas CT retains a role for calcifications, thoracic lesions, masses, and anatomy in selected situations.

The differential diagnosis remains open throughout the clinical history. Chest-wall pain, reflux, pleuritis, and other causes may overlap; embolism, dissection, and ischemia require exclusion when suggested by the presentation. Pain and fatigue during prednisone tapering may also reflect withdrawal effects. When symptoms repeatedly lack inflammatory correlates, it is reasonable to reconsider the pain mechanism before intensifying immunomodulation. This verification should be presented as a search for an explanation and effective treatment, not as denial of the disorder or devaluation of the reported history.

Definition of phenotype and further etiologic investigations

Specialist characterization describes frequency, intensity, and context of recurrences, together with the ability to achieve remission and reduce medications. A single new episode after years of wellness does not require the same strategy as multiple attacks during adequate therapy. Symptom-free intervals, available markers, imaging results, healthcare visits, and the lowest corticosteroid dose below which disease reactivates are recorded. It is useful to distinguish recurrence after withdrawal, resistance during treatment, and inability to continue because of adverse effects: these are different problems requiring different solutions.

The autoinflammatory phenotype is suggested by episodes with fever, marked CRP elevation, serositis, and response to treatments acting on innate immunity. It is not a label to assign solely on the basis of recurrence. An autoimmune phenotype instead requires integration with manifestations and investigations of systemic disease. In clinical pictures with low inflammatory expression, both local inflammation poorly represented in blood and noninflammatory causes of pain must be considered. The distinction is operational: it helps select the target and avoids subjecting all patients to the same therapeutic sequence regardless of the data.

The autoimmune investigations are selected according to the clinical picture. Suspected lupus may require complement, appropriate autoantibodies, urinalysis, and organ assessment; persistent arthritis, vascular manifestations, or other symptoms may point in different directions. Extensive panels in people without clues produce incidental results and may create unsupported diagnoses. A previous positive result merits reassessment if the phenotype has changed, but automatic repetition does not guarantee greater accuracy. Rheumatology consultation becomes particularly useful when pericardial treatment must be coordinated with kidney, joints, skin, or other organs.

The genetic investigation is reserved for justified suspicion: family history, childhood or young-onset disease, periodic febrile attacks, polyserositis, and other consistent manifestations may justify it. Selection of a panel or broader analysis and interpretation require specific expertise. A negative result does not eliminate every biological predisposition, whereas a positive result must be verified for clinical relevance. It is inappropriate to communicate an inherited syndrome on the basis of a variant of uncertain significance or a favorable response to colchicine. Genetic counseling also helps clarify familial implications of a truly pathogenic result.

The search for infections and neoplasia is reopened when new warning signs emerge, not with every identical attack that has already been well characterized. Persistent fever, immunosuppression, weight loss, lymphadenopathy, a large collection, or a change in imaging may require blood cultures, tuberculosis assessment, CT, or fluid analysis. Drainage is not indicated merely to count a recurrence, but may become necessary for hemodynamic or diagnostic reasons. Cytology, cultures, and other tests should be planned around the clinical question. Biopsy may have value in selected unresolved cases without becoming a universal requirement before treating a typical idiopathic form.

Before therapy capable of modifying immunity, the safety profile is defined: relevant active or latent infections, vaccination status, complete blood count, hepatic and renal function, comorbidities, and interactions. Tuberculosis assessment and possible testing for hepatitis or HIV depend on the drug, risk, and relevant protocols. For rilonacept, a baseline lipid profile is also useful. These checks do not serve to demonstrate pericarditis, but to select and monitor treatment. This distinction avoids confusing a safety requirement with etiologic evidence.

Characterization also includes cardiac function and target organs. Hepatic congestion, renal deterioration, arrhythmias, and myocardial abnormalities change priorities and follow-up intensity. Risk of constriction is not measured by counting attacks: functional signs and etiologic interpretation are required. Exercise limitation may also depend on anemia, deconditioning, or steroid toxicity. Making these components explicit allows response to be measured against appropriate targets and prevents a normalized biomarker from being mistaken for complete recovery of the entire clinical condition.

Conventional treatment of the attack and prevention of further recurrences

A first recurrence does not automatically imply the need for a biologic drug. In appropriate forms, a combination of aspirin or NSAIDs and colchicine is used, with a sufficient anti-inflammatory dose and a duration consistent with response. An attack occurring after premature discontinuation may respond to correct reintroduction of first-line therapy; a documented recurrence during an adequate regimen requires broader reasoning. The acute goal is to achieve clinical and objective control, while the preventive goal is to maintain that control during subsequent tapering, avoiding repeated cycles of stopping and restarting.

For adults with an adequate safety margin, usual regimens include ibuprofen 600-800 mg every eight hours or aspirin 750-1,000 mg every eight hours. Choice takes into account coronary artery disease, renal function, gastrointestinal and bleeding risk, and concomitant medications. Gastroprotection is generally added and simultaneous use of multiple NSAIDs is avoided. The dose is maintained until control is achieved and then progressively reduced. In more difficult cases, the pace may be slower than after the first episode: there is no fixed duration that replaces assessment of remission.

The colchicine is commonly administered at 0.5 mg once daily for body weight below 70 kg and 0.5 mg twice daily at 70 kg or above, without a loading dose, with adjustments for organ function and tolerability. In recurrence, a duration of at least six months is planned, often longer when required by the course. It is generally maintained while other drugs are tapered and discontinued only after satisfactory stability. Prevention depends on tolerable continuous exposure: significant diarrhea requires reassessment because it can compromise adherence, hydration, and safety.

Randomized evidence is strong. In the CORP trial, concerning the first recurrence, the rate of further recurrences at 18 months was 24% with colchicine and 55% with placebo, in addition to conventional treatment. In CORP-2, among 240 adults with at least two previous recurrences, a new recurrence occurred in 21.6% of the colchicine group and 42.5% of the placebo group. These studies support the role of the drug beyond the first attack, but they are not direct comparisons with biologics and do not justify ranking therapies merely by comparing percentages obtained in different populations.

The interactions can make an otherwise usual dose hazardous. CYP3A4 and P-glycoprotein inhibitors, including some macrolides, azole antifungals, and immunosuppressants, can increase colchicine exposure; renal or hepatic impairment amplifies the problem. Muscle weakness, cytopenias, and significant gastrointestinal toxicity require prompt evaluation. With NSAIDs, renal function, blood pressure, fluid retention, and bleeding are monitored, especially during prolonged therapy. Review of prescriptions from other specialists is part of recurrence prevention because an effective but unsafe treatment cannot be maintained.

The corticosteroids are indicated when a systemic disease requires them, when first-line therapy is contraindicated, or when the clinical picture is uncontrolled and the overall strategy justifies their use. They should not be used automatically for every recurrence. Low- or moderate-dose prednisone, approximately 0.2-0.5 mg/kg/day, is generally preferred, while maintaining colchicine and, when appropriate, the nonsteroidal component. Relevant infections must be excluded or treated. High doses may rapidly suppress symptoms without providing a proportional durable advantage relative to their greater toxicity.

The prednisone taper begins after remission and proceeds with particular caution near doses at which flares have previously occurred. Below approximately 15 mg/day, reductions of 1.25-2.5 mg separated by two to six weeks may be necessary, adapted to history and cumulative exposure. This approximate guidance does not replace assessment of the adrenal axis and individual risk. Isolated recurrence of fatigue or myalgia does not automatically require returning to high doses. Preferably, one component is changed at a time so that the response can be interpreted and anti-inflammatory protection maintained during tapering.

When control requires persistent steroid exposure, or recurrences continue despite colchicine and adequate therapy, a strategy that reduces corticosteroid requirements should be considered. Escalation should not wait for osteoporosis, diabetes, or repeated infections to appear. At the same time, it should be justified by documented activity, not merely by the desire to eliminate every chest sensation. The choice among anti-interleukin-1 therapy, treatment of autoimmune disease, and other options depends on the phenotype. The need for prolonged therapy does not prove irreversible pericardial damage, but indicates that remission still requires pharmacologic support.

Interleukin-1 blockade and treatment of refractory forms

The interleukin-1 inhibitors have changed management of recurrent forms with inflammatory activity, especially when colchicine does not control the disease and corticosteroid dependence develops. Selection should establish that recurrence is real, that no untreated infection is present, and that an inflammatory target is plausible. Contemporary recommendations allow these drugs to be considered in nonresponders without requiring everyone to undergo prolonged steroid exposure. Availability and authorized indications differ by setting and should be verified at the time of prescribing.

The anakinra is an interleukin-1 receptor antagonist and blocks signaling by alpha and beta. In adults it is commonly used at 100 mg subcutaneously every day; pediatric or weight-based regimens require specialist management, and severe renal impairment may necessitate modification of the dosing interval. Clinical benefit may appear rapidly, but an early response does not mean permanent disappearance of the predisposition. Treatment should be incorporated into a program that includes tapering of previous drugs, monitoring, and a future discontinuation strategy.

In the AIRTRIP trial, 21 patients with multiple recurrences, elevated CRP, colchicine resistance, and corticosteroid dependence initially received anakinra and were then randomized to continuation or withdrawal through placebo. Recurrence occurred in 2 of 11 assigned to anakinra and 9 of 10 assigned to placebo. The result is important but comes from a small study and a highly selected population after an initial response to the drug. It does not demonstrate that every chest pain episode with normal CRP will benefit from the same strategy, nor does it permit direct numerical comparison with other drugs studied under different conditions.

The IRAP registry expanded experience to 224 patients with colchicine-resistant, corticosteroid-dependent disease. During anakinra treatment, reductions in recurrences, urgent visits, and hospitalizations were observed together with lower steroid use. Regimens with more than three months at full dose followed by tapering for more than three months were associated with a lower recurrence risk. This is observational evidence: patient selection, spontaneous course, and concomitant treatments prevent interpretation as proof of a universal optimal duration.

The rilonacept is a fusion protein that acts as a soluble receptor capable of binding interleukin-1 alpha and beta. The studied adult regimen uses 320 mg subcutaneously as a loading dose and 160 mg once weekly. In RHAPSODY, after an initial treatment phase and transition from conventional drugs, 61 responsive patients were randomized: recurrence occurred in 2 of 30 continuing rilonacept and 23 of 31 receiving placebo. The hazard ratio was 0.04. The randomized-withdrawal design strongly documents maintenance of benefit in selected responders, without proving cure after discontinuation.

On the basis of these studies, there is no direct comparison establishing superiority of anakinra over rilonacept or vice versa for every patient. Injection frequency, available experience, renal function, access, costs, preferences, and clinical profile contribute to the choice. Biologic monotherapy may be reached in selected patients according to a transition program, whereas in others colchicine or another component is initially maintained. Combinations and tapering should not be mechanically copied from a single study protocol: the aim is to reduce total treatment burden without losing disease control.

The monitoring includes infections, local reactions, complete blood count, and liver function, with additional assessments depending on the drug and context; lipids are also monitored with rilonacept. Injection-site reactions may be frequent and initially troublesome, but their management must distinguish a common local event from infection or a systemic reaction. Live vaccines and concomitant immunosuppression require planning. New fever, cytopenias, or infectious symptoms should not automatically be interpreted as a pericarditic attack. High efficacy observed in trials does not eliminate the need to monitor individual risks.

The duration of cytokine blockade remains a complex decision. Disease may be silent during treatment and reappear when it is stopped. Abrupt discontinuation, especially after only a short period of control, may therefore be inappropriate; gradual tapering is often used with anakinra, although no single sequence has been validated for everyone. Criteria include duration of stability, previous attempts, absence of steroids, markers, and imaging in relevant cases. It is incorrect to maintain therapy indefinitely solely because of residual LGE, or to discontinue it because one blood test shows normal CRP.

The azathioprine is a slow-acting option in selected cases, especially when steroid exposure must be reduced or an autoimmune component treated. Choice and dose escalation require assessment of myelotoxicity risk, interactions, and liver function with hematologic monitoring; when appropriate, thiopurine metabolism is also considered. It does not replace immediate control of a painful attack. Other immunosuppressants are chosen mainly according to the underlying systemic disease. The evidence base in isolated idiopathic pericarditis is more limited than the dedicated trials of colchicine and anti-interleukin-1 therapies.

The intravenous immunoglobulins may be considered as rescue treatment after failure or inability to use other therapies. In the multicenter cohort by Collini and colleagues, 43 refractory patients received cycles of 400-500 mg/kg/day for five days, with possible repetitions; a reduction in events was observed during follow-up. Lack of randomization and case selection limit causal attribution and do not define the optimal place in the treatment sequence. Thrombotic risk, renal function, volume overload, and infusion reactions require attention. Favorable data do not make this treatment a universal first choice.

Among the developments studied is goflikicept, another approach to interleukin-1 trapping evaluated in a phase II/III study of recurrent idiopathic pericarditis. These results expand research possibilities but should not be translated into automatic equivalence of availability and indications across countries. Belonging to the same biological area does not make all agents interchangeable, including those targeting only one form of interleukin. Molecules directed at other steps of inflammation require evaluation in adequate studies before becoming routine treatment.

The pericardiectomy may be discussed in exceptionally refractory cases with a certain diagnosis, severe impairment of life, and failure or intolerance of appropriate options. The indication is distinct from that for irreversible constriction and requires an expert center, because the balance of benefit and risk depends on etiology, extent of adhesions, epicardial involvement, general condition, and the technically achievable completeness of resection. Chronic pain not documented as inflammatory is an insufficient basis for proposing it. Surgery does not necessarily eliminate a systemic autoimmune or autoinflammatory disease also responsible for extracardiac manifestations.

Follow-up, treatment withdrawal, and prognosis

Follow-up should document sustained remission, not merely immediate improvement after an increase in dose. Symptom trend, clinical examination, CRP when informative, tolerability, and functional capacity are assessed. Echocardiography is repeated according to the collection and clinical course; magnetic resonance imaging is reserved mainly for cases in which uncertainty about activity persists or the result could change an important decision. Repeating imaging at rigid intervals without a question does not guarantee safer withdrawal. Quality of comparisons and temporal coherence are often more useful than the number of examinations.

The planned discontinuation considers the drug, duration of stability, and previous attempts. Reductions are preferably separated so that the response to each step can be recognized. Colchicine is often maintained until an advanced phase of the pathway; corticosteroids and biologics require specific strategies. If a symptom returns, it is first determined whether this is new activity, an effect of dose reduction, or another cause. A shared plan for whom to contact and which tests to obtain limits both dangerous delays and unsupervised use of repeated corticosteroid courses.

During an active recurrence, intense exercise is restricted. Return occurs after clinical control and control of relevant findings, with progression appropriate to previous level and duration of inactivity. In the presence of myocarditis, arrhythmias, or dysfunction, resumption follows more cautious and specific criteria. It is incorrect to prohibit every activity indefinitely solely because of a history of recurrences, but it is also inappropriate to permit major exertion simply because pain is suppressed by medication. Recovery includes sleep, conditioning, work activity, and reduction of fear of movement.

Situations such as pregnancy, desire for conception, pediatric age, and frailty require dedicated planning. Disease control before conception allows compatible therapy to be chosen and urgent changes during a flare to be avoided. Safety and use of individual drugs depend on gestational age and available data: NSAIDs, colchicine, corticosteroids, and biologics cannot be treated as a single category. In children, weight, growth, and suspicion of autoinflammatory disease are considered; in older adults, renal function and polypharmacy may determine the therapeutic margin more than severity of the attack itself.

The cardiac prognosis of recurrent idiopathic forms is often better than the pain and number of healthcare visits might suggest. A succession of attacks does not necessarily mean progression toward tamponade, constriction, or heart failure. Etiology and any signs of myocardial injury or hemodynamic compromise have greater prognostic value. This message must coexist with recognition of morbidity: a low-mortality disease may be highly disabling and justify effective specialist treatment to reduce attacks and medication exposure.

The patient-reported outcomes complete the assessment. In the RHAPSODY analysis focused on quality of life and sleep, control during rilonacept treatment was accompanied by improved questionnaire scores, whereas recurrences during withdrawal worsened these dimensions. This finding does not replace safety surveillance, but shows why benefit should not be judged solely by the number of hospitalizations. Successful treatment allows recovery of autonomy, planning of activities, and reduction of the daily burden of disease together with control of inflammatory findings.

Complications and prevention of cumulative harm

The most common practical complication is the cycle of flares: new attacks prompt increases in medication, tapering attempts cause alarm, and total treatment duration becomes prolonged. Part of this cycle may reflect persistent inflammation; another part may depend on imprecise classification of episodes or pain from a different mechanism. Confirming activity before major changes and using a stable preventive strategy reduce the risk of turning every variation in symptoms into a new treatment cycle.

The tamponade remains possible when a collection with compressive effect accumulates, but it is not an inevitable outcome of idiopathic recurrences. New dyspnea at rest, hypotension, disproportionate tachycardia, jugular venous distension, or syncope requires urgent assessment. Drainage addresses hemodynamic compromise and other indications related to the collection, whereas control of inflammation addresses a distinct problem. A history of benign attacks does not justify ignoring an important clinical change, especially if anticoagulation, trauma, infection, or neoplasia has appeared in the meantime.

The constriction should be suspected in the presence of systemic congestion, ascites, edema, and impaired filling, not merely because many recurrences have occurred. Transient inflammatory forms may improve; stable fibrosis requires a different assessment. Bacterial, tuberculous, and other specific etiologies carry a different risk from idiopathic disease. Associated myocardial involvement may also explain heart failure or arrhythmias and should be distinguished from pericardial restriction. Functional diagnosis prevents attributing to the pericardium symptoms caused by another cardiac mechanism.

The iatrogenic harm may become the most burdensome part of a long clinical history. Bleeding and nephrotoxicity from NSAIDs, intolerance or toxicity from colchicine, metabolic and bone abnormalities from steroids, and infections during immunomodulation require active prevention. Bone protection, metabolic surveillance, and laboratory monitoring are adjusted to actual treatment and individual risk. New renal failure may alter drug elimination and turn a previously tolerated regimen into a dangerous one. For this reason, periodic monitoring concerns more than CRP alone.

The adrenal suppression after prolonged corticosteroid treatment makes the final withdrawal phase delicate. Fatigue, nausea, myalgia, and reduced tolerance to stress may overlap with symptoms attributed to recurrence. Distinction requires history, clinical assessment, and possibly specific testing; abrupt discontinuation is not a safe solution. On the other hand, interpreting every malaise as pericardial activity can prevent tapering for years. Management must therefore separate control of inflammation from endocrine recovery while coordinating them within the same pathway.

Finally, disability and psychological distress may accumulate even without permanent cardiac damage. Disturbed sleep, absence from work, loss of conditioning, and fear of being without treatment deserve explicit attention. A clear follow-up program, shared remission criteria, and instructions on when to reassess urgently help restore predictability. Psychological support, when useful, complements treatment of the disease and does not replace it. Preventing cumulative harm means achieving the best possible balance among control of attacks, medication safety, and recovery of daily life.

Bibliography
1. Schulz-Menger J et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis. European Heart Journal. 2025;46(40):3952-4041.
2. Wang TKM et al. 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Diagnosis and Management of Pericarditis: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2025;86(25):2691-2719.
3. Klein AL et al. Pericardial Diseases: International Position Statement on New Concepts and Advances in Multimodality Cardiac Imaging. JACC: Cardiovascular Imaging. 2024;17(8):937-988.
4. Adler Y et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2015;36(42):2921-2964.
5. Mauro AG et al. The Role of NLRP3 Inflammasome in Pericarditis: Potential for Therapeutic Approaches. JACC: Basic to Translational Science. 2021;6(2):137-150.
6. Imazio M et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Annals of Internal Medicine. 2011;155(7):409-414.
7. Imazio M et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. The Lancet. 2014;383(9936):2232-2237.
8. Brucato A et al. Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. JAMA. 2016;316(18):1906-1912.
9. Klein AL et al. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. New England Journal of Medicine. 2021;384(1):31-41.
10. Imazio M et al. Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study. European Journal of Preventive Cardiology. 2020;27(9):956-964.
11. Collini V et al. Human intravenous immunoglobulins for recurrent pericarditis: a multicentre cohort study. European Journal of Preventive Cardiology. 2026;33(5):766-771.
12. Myachikova VY et al. Treatment of Idiopathic Recurrent Pericarditis With Goflikicept: Phase II/III Study Results. Journal of the American College of Cardiology. 2023;82(1):30-40.
13. Brucato A et al. Interleukin-1 Trap Rilonacept Improved Health-Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY. Journal of the American Heart Association. 2022;11(20):e023252.
14. Imazio M et al. Risk of constrictive pericarditis after acute pericarditis. Circulation. 2011;124(11):1270-1275.
15. Spodick DH. Acute cardiac tamponade. New England Journal of Medicine. 2003;349(7):684-690.
16. Imazio M et al. Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation. 2011;123(10):1092-1097.